

ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Midatech Pharma

MTPH  24.57p ▲ 0.1 0.3%Highly Speculative, Micro Cap, **Sucker Stock**

Market Cap

£24.1m

Quality

8

Enterprise Value

£20.7m

Value

0

Revenue

£576k

Momentum

26


Market Cap Rank

1399th / 1783

StockRank™

3

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum

Relative Strength (%)

1m -3.0% ●

3m -4.6% ●

1yr -20.2% ●

Volume Change (%)

10d v 3m -68.9% ●

Price vs... (%)

52w High -52.8% ●

50d MA -3.49% ●

200d MA -14.6% ●

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (ttm) n/a

PEG Ratio (ttm) n/a

EPS Growth (ttm) n/a %

Dividend Yield (ttm) n/a %

Valuation (ttm)

Price to Book Value 6.43

Price to Tang. Book 6.43

Price to Free Cashflow n/a

Price to Sales 41.9

EV to EBITDA n/a

Quality

vs. industry vs. market


Return on Capital -178.8 %

Return on Equity -190.9 %

Operating Margin -1,377 %

Health Trend Piotroski F-Score

4



Bankruptcy Risk Altman Z2-Score

-26.6



Earnings Manipulation Risk

N/A

Magic Formula Score

2583 2% E-



Other Ratios

Leverage (ttm)	total	-intang	+pension
Gross Gearing	% 21.6	21.6	21.6
Net Gearing	% -90.4	-90.4	-90.4
Cash / Assets	% 50.8		50.8

Liquidity (ttm)	Efficiency (ttm)
Curr. Ratio 1.83 ●	Asset Turnover 0.064
Quick Ratio 1.83 ●	Rec's Turnover 0.23
Interest Cov. -7.40 ●	Stock Turnover n/a

Recent History

vs. industry vs. market

Latest interim period (ended 30th Jun '21) vs. prior year

Sales Growth 138.7 %

EPS Growth n/a %

3yr Compound Annual Growth Rate

Sales Growth -29.7 %

EPS Growth n/a %

DPS Growth n/a %

Margin of Safety (beta)

Broker Target

Relative to Sector -22%

Stability Value (EPV) -77%

Screens Passed 1


MTPH qualifies for **Altman Z-Score Screen**
(in **Short Selling**).[View Screen](#) · [View Checklist](#)

Financial Summary

Balance Sheet · Income Statement · Cashflow


Year End 31st Dec		2015	2016	2017	2018	2019	2020	TTM	2021E	2022E	CAGR / Avg
Revenue	£m	1.38	1.32	0.99	1.94	0.67	0.34	0.58	13.4		-24.2%
Operating Profit	£m	-12.9	-9.65	-13.3	-11.8	-11.3	-23.0	-7.93			
Net Profit	£m	-10.1	-20.2	-16.1	-15.0	-10.1	-22.2	-7.92	-15.3		
EPS Reported	p	-699.6	-336.6	-449.5	-334.2	-49.9	-51.8	-13.2			
EPS Normalised	p	-450	-336.6	-411.4	-330.8	-49.9	-32.7	-12.3	-2.70		
EPS Growth	%								n/a	n/a	
PE Ratio	x							n/a	n/a	n/a	
PEG	x							n/a	n/a	n/a	
Profitability											
Operating Margin	%	-939.5	-729.6	-1,342	-609.6	-1,679	-6,717	-1,377			-2,003%
ROA	%		-10.2	-22.1	-29.8	-35.6		-78.2			
ROCE	%	-23.5	-20.4	-32.5	-65.7	-44.9	-337.4	-178.8			-87.4%
ROE	%		-13.3	-29.1	-40.2	-50.1	-168.9	-190.9			-60.3%
Cashflow											
Op. Cashflow ps	p	-860.5	-714.9	-497.4	-433.6	-35.4	-21.7	-11.7			
Capex ps	p	64.1	74.6	57.0	7.87	1.74	0.49	0.68			-62.3%
Free Cashflow ps	p	-924.6	-789.5	-554.4	-441.5	-37.1	-22.2	-12.4			
Dividends											
Dividend ps	p										
Dividend Growth	%										
Dividend Yield	%										
Dividend Cover	x										
Balance Sheet											
Cash etc	£m	16.2	17.6	13.2	2.34	10.9	7.55	4.20			-14.1%
Working Capital	£m	11.2	13.0	10.2	3.15	8.07	6.29	3.19			-11.0%
Net Fixed Assets	£m	2.37	3.21	2.99	2.45	4.78	0.54	1.25			-25.6%
Net Debt	£m	-14.2	-15.5	-6.66	-1.09	-4.85	-7.29	-3.39			
Book Value	£m	46.9	45.7	34.7	16.9	19.6	6.72	3.75			-32.2%
Average Shares	m	1.44	1.83	2.60	3.10	18.3	42.8	45.3			+97.0%
Book Value ps	p	2,740	1,846	1,119	545.1	83.2	10.7	5.92			-67.0%

Graphical History Current Fiscal Year 2021



Broker Forecasts				31st Dec 2021			31st Dec 2022		
Price Target: 0.66 (+169.41% above Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				-15.3m	-2.70	-	-	-	-
1m Change				-	-	-	-	-	-
3m Change				-	-	-	-	-	-

Broker Consensus Trend



Profile Summary



Midatech Pharma PLC is a drug delivery technology company, which is focused on improving the bio-delivery and biodistribution of medicines. The Company has developed three in-house technology platforms, each with its own mechanism to improve delivery of medications to sites of disease. The Company's platform includes Q-Sphera platform, MidaSolve platform and MidaCore platform. Q-Sphera platform is a micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). MidaSolve platform is a nanotechnology used to dissolve insoluble drugs, which can be administered in liquid form directly and locally into tumors. MidaCore platform is a nanotechnology used for targeting medications to sites of disease. It has a pipeline of approximately 10 earlier stage programmes, which includes MTD211, MTD214, MTD220, MTX213, MTX214, MTX216, MTX110, MTX110, MTX110 and MTX114.

Directors: Rolf Stahl (NEC) 77, Simon Turton (NID) 54, Simon De Vries (NED) 61, Stephen Stamp (CEO) 59, Dmitry Zamoryakhin (CSO), Steve Damment (EVP), Paul Seaman (VPR), Fiona Sharp (OTH), Sam Barker (OTH), Kelly Conlon (VPR), Nitu Sharma (OTH).

No. of Employees: 40

No. of Shareholders: n/a

Last Annual	December 31st, 2020	Sector	Healthcare
Last Interim	June 30th, 2021	Industry	Biotechnology & Medical Research
Incorporated	September 12, 2014	Index	FTSE Aim All Share
Public Since	December 8, 2014	Exchange	London Stock Exchange (AIM)
Shares in Issue	98,468,387	Eligible for	an ISA? a SIPP?
Free Float	85.8m (87.1%)		




Address Oddfellows Hse 19 Newport Road, ABINGDON, CF24 0AA, United Kingdom
Web <http://www.midatechpharma.com/>
Phone +44 1235 841575
Contact ()
Auditors MAZARS LLP

MTPH Share Price Quote

MTPH Share Price **Day's Change**
 GBP
24.57p **▲ 0.1 0.3%**
 Traded 9:54am · Minimum 15 min delayed · NMS: 1.50k

Volume	65,316	Bid - Ask	24.0 - 25.0	Low - High	0.0 - 0.0	Spread	407bps
Avg Vol (3m)	153,184	Open - Close	24.5 - 24.5	12m Range	24.5 - 49.0	Beta	2.07

MTPH Share Price Performance



Latest MTPH News Announcements (delayed)

More »

- 17th Sep BRIEF-Midatech Pharma H1 Net Loss After Tax 3.11 Mln Stg
- 17th Sep Midatech Pharma PLC - Interim results
- 16th Sep RCS - Midatech Pharma PLC - Official Opening of New Cardiff Headquarters
- 6th Sep Midatech Pharma PLC - Notice of Interim Results
- 17th Aug Midatech Pharma PLC - Change of Registered Office

Upcoming MTPH Events

Thursday 28th April, 2022 (Estimate)
 Full Year 2021 Midatech Pharma PLC Earnings Release

Recent ↓

Industry Peer Group

- Faron Pharmaceutic...**
Compare vs MTPH
- Bioventix**
Compare vs MTPH
- Redx Pharma**
Compare vs MTPH
- E-Therapeutics**
Compare vs MTPH
- Allergy Therapeuti...**
Compare vs MTPH
- Avacta**
Compare vs MTPH
- Synairgen**
Compare vs MTPH
- Silence Therapeuti...**
Compare vs MTPH

Healthcare

Biotechnology & Medical Research

